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ABSTRACT
Objectives: To develop algorithms for a conversion of disease-speciﬁc
quality-of-life into health state values for morbidly obese patients before
or after bariatric surgery.
Methods: A total of 893 patients were enrolled in a prospective cross-
sectional multicenter study. In addition to demographic and clinical data,
health-related quality-of-life (HRQoL) data were collected using the
disease-speciﬁc Moorehead-Ardelt II questionnaire (MA-II) and two
generic questionnaires, the EuroQoL-5D (EQ-5D) and the Short Form-6D
(SF-6D). Multiple regression models were constructed to predict EQ-5D-
and SF-6D-based utility values from MA-II scores and additional demo-
graphic variables.
Results: The mean body mass index was 39.4, and 591 patients (66%) had
already undergone surgery. The average EQ-5D and SF-6D scores were
0.830 and 0.699. The MA-II was correlated to both utility measures
(Spearman’s r = 0.677 and 0.741). Goodness-of-ﬁt was highest (R2 = 0.55
in the validation sample) for the following item-based transformation
algorithm: utility (MA-II-based) = 0.4293 + (0.0336 ¥ MA1) + (0.0071 ¥
MA2) + (0.0053 ¥ MA3) + (0.0107 ¥ MA4) + (0.0001 ¥ MA5). This
EQ-5D-based mapping algorithm outperformed a similar SF-6D-based
algorithm in terms of mean absolute percentage error (P = 0.045).
Conclusions: Because the mapping algorithm estimated utilities with only
minor errors, it appears to be a valid method for calculating health state
values in cost-utility analyses. The algorithm will help to deﬁne the role of
bariatric surgery in morbid obesity.
Keywords: bariatric surgery, economics, EQ-5D, health status indicators,
quality of life.
Introduction
Obesity is an increasingly common disorder in Western societies
[1,2]. Health spending for overweight and obese people has risen
rapidly, mainly because of the various comorbidities associated
with obesity, such as type 2 diabetes, hypertension, dyslipidemia,
gallstone disease, knee osteoarthritis, sleep apnea or even cancer
[3]. Different degrees of obesity can be deﬁned by the body mass
index (BMI, deﬁned as weight in kg/height in m2). Conservative
measures, such as diets, are effective only for milder degrees of
overweight and obesity [4,5]. Since over 15 years, there is consen-
sus that morbid obesity (BMI > 40 kg/m2 or BMI > 35 kg/m2 with
obesity-associated comorbidity) represents an indication for a
weight-loss (bariatric) surgical procedure [5–8], such as gastric
banding or gastric bypass. Today, bariatric surgery is a well-
studied and increasingly popular treatment modality [9]. Between
1998 and 2002, the number of bariatric operations performed in
the USA has risen nearly ﬁvefold [10], and in Europe a similar rise
can be expected from epidemiological data [11]. In many health-
care systems, however, uncertainty about the cost-effectiveness
and utility of bariatric surgery remained. In addition, it remains to
be deﬁned which type of bariatric procedure is best for which
grade of obesity [9].
Because obesity affects nearly every aspect of our physical,
mental, social, and emotional health, accurate assessment of
quality-of-life is important when describing the effectiveness of
weight-loss therapy [12,13]. The majority of literature on bari-
atric surgery assessed and reported health-related quality-of-life
(HRQoL) using the Moorehead-Ardelt II questionnaire (MA-II),
which is applicable to patients before or after weight-loss therapy
[14,15]. The MA-II includes only six items and takes about a
minute to complete. MA-II data can combined with a score based
on weight loss and complications. This Bariatric Analysis and
Reporting Outcome System (BAROS) can be used to deﬁne
failure or success of surgery [16]. Most surgeons prefer the MA-II
or other similar instruments over generic questionnaires, because
disease-speciﬁc instruments offer a higher responsiveness [17].
The BAROS has been endorsed by various professional societies
for use in clinical practice [18]. Currently, however, it is not
possible to generate utilities from trials that have used the MA-II.
Because utilities are the basis for the calculation of quality-
adjusted life-years, they also are an essential part of cost-
effectiveness analyses, health technology assessment, and in any
health-care decision-making process.
The primary goal of this study therefore was to map the
relationship between the MA-II and EQ-5D-based utility values.
A calculation of health state values based on a conversion algo-
rithm would allow health economists to use MA-II data from
previous and future trials. A secondary goal was to compare the
resulting algorithms between EQ-5D and SF-6D.
Methods
Study Design
The study was a cross-sectional survey conducted in four Euro-
pean countries between August and December 2007. Five leading
centers of bariatric surgery took part in the study. The choice of
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centers was made taking into account the need to select from a
variety of bariatric surgical procedures. By including patients
with different cultural backgrounds, the study aimed at achieving
better generalizability of results. Because a formal power calcu-
lation is not possible for a regression analysis, the sample size
was decided to be approximately 800 patients. This number was
chosen on practical grounds and on the basis of previous similar
studies.
All patients were informed about the study by their surgeon
and provided written informed consent to participate in the
study. The study was approved by the Ethics Committee of the
University of Witten/Herdecke. To ensure accuracy of medical
data, the sites were visited during the study.
Study Sample
Because bariatric surgery can also lead to speciﬁc side effects
impacting on HRQoL, the study sample included both preopera-
tive and postoperative patients. This way of sampling allowed for
a diversity of different health states and different degrees of
obesity, even including patients who had returned to normal body
weight. Patients were considered eligible if they either were sched-
uled for bariatric surgery or had received any bariatric operation
in the past. All patients were morbidly obese, either currently or in
the past. Nevertheless, we excluded patients who had had their
index operation within the last 3 months, because the short-term
sequelae of surgery might have interfered with accurate assess-
ment of HRQoL. Each center consecutively included patients who
were seen in the outpatient clinic.
Data were collected on sociodemographic (sex and age) and
clinical characteristics (current weight, height, and metabolic,
pulmonary, cardiovascular or other comorbidities). The severity
of each comorbiditywas deﬁned asmoderate (requiring no or only
occasional medical therapy) or severe (requiring regular drug
treatment). In postoperative patients, the preoperative status
(weight and comorbidities) was recorded in addition to surgery-
related data (date and type of surgery, complications). For those
patients, who underwent a staged procedure (e.g., sleeve gastrec-
tomy followed by biliopancreatic diversion with duodenal switch)
or who had to be converted to another type of procedure, only the
ﬁrst operation was counted as index operation.
Questionnaires
The MA-II contains six questions, which were scored on a scale
from 1 to 10. These questions address mood, physical function,
social relationships, ability to work, sexuality, and eating behav-
ior. In each question, the ends of the scale are labelled by descrip-
tors and highlighted by colored icons. Higher scores represent
better HRQoL. A summary score can be calculated, which ranges
between 6 and 60 (or alternatively between -3 and 3). Values
greater than 42 (or 1, respectively) indicate good HRQoL.
Although bariatric surgeons in many countries currently are
using the MA-II, so far it is validated only in English [14].
Therefore, translations of the MA-II into German, Czech, Italian,
and Spanish were carried out with the permission of the copy-
right owners. In each country, these translations were carefully
checked for accurate wording by the respective surgeons. The
data generated in the present study will also be used to formally
validate the translated versions of the MA-II. This validation
analysis will follow in a subsequent publication. Given the sim-
plicity of wording and the partly graphical format of the MA-II,
however, it appears unlikely that the different language versions
produced different results.
The EuroQoL-5D (EQ-5D) is a commonly used generic
instrument which contains ﬁve items and a visual analogue scale
(EQ-VAS) [19]. The EQ-5D deﬁnes ﬁve dimensions of health:
mobility, self-care, usual activities, pain, and anxiety of depres-
sion. We used the weights published by Greiner et al. [20] to
calculate a single summary score from the ﬁve descriptive items
of the EQ-5D.
The Short Form-6D (SF-6D) is a preference-based measure of
health, based on a subset of 11 questions from the SF-36. In the
present study, country-speciﬁc versions of the revised instrument
(SF-36v2 with 4-week recall) were used. Although the SF-36
measures eight dimensions of HRQoL [21], only six of these
dimensions form the basis of the SF-6D: by using the algorithm
developed by Brazier et al. [22], we computed health state values
from 11 items of the SF-36.
Missing data were replaced for the SF-36 by using the half-
scale rule. When calculating the summary score for the MA-II,
missing values for item 5 (sexuality) were estimated by replacing
them with the average of the other ﬁve items. No other missing
data were generated. The completeness of answers to the differ-
ent questions exceeded 96% in all questionnaires.
Model Selection
Initially, the total sample was randomly subdivided into two equal
sized groups. Regressionmodelswere developed on the ﬁrst half of
the sample, whereas the second half was used as cross-validation
sample. Multivariate linear regression models were used to estab-
lish prediction models of EQ-5D and SF-6D. Because missing data
were not estimated, the actual number of valuations varied in the
different analyses. Utility index values were treated as continuous
variables. To include HRQoL in the prediction model, the MA-II
was used in two different ways: ﬁrst, as a summary score, and
second, as a set of six single items. Because we aimed for a
simple-to-use and robust algorithm, only very few demographic
variables were included in the models: age, sex, and current BMI.
Additionally, the country (transformed into dummy variables)
was studied. Furthermore, ﬁrst-degree interaction terms were
added to the model. To assess the inﬂuence of ceiling effects, we
compared the results of regression analyses among pre- and
postoperative patients, because postoperative patients are gener-
ally more likely to report HRQoL to be normal or even supernor-
mal. AlthoughHRQoLvaries by social class and income,we chose
not to incorporate such variables, because they are difﬁcult to
assess accurately in clinical routine.
The R2 statistic provided a measure of the goodness-of-ﬁt of
the regression model. Regression residuals were examined to
identify potentially suitable nonlinear models. The absolute
deviation between actual and predicted utility values served as a
secondary indicator of model performance. Predicted values of
EQ-5D exceeding 1.0 were truncated to this boundary value. The
differences between observed and predicted utility values were
divided by the observed value, thus calculating the mean (and
median) absolute percentage error (MAPE). The MAPE was used
as additional methods to describe the relative overall ﬁt of the
model.
Additional Statistical Tests
Comparisons between different subgroups of patients were
carried out with Student’s t and chi-square tests. The differences
between EQ5D and SF6D validation results were analyzed by
Wilcoxon signed-rank test for paired data. Correlations were
evaluated by Pearson’s and Spearman’s coefﬁcient of correlation.
All calculations of R2 were carried out using Pearson’s coefﬁcient
of correlation. All statistical analyses were performed using SPSS,
version 15.0 (SPSS Inc., Chicago, IL, USA).
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Results
Patients
Similar to other studies on morbid obesity, this cohort had had a
clear preponderance of females (79%). The patients’ current BMI
ranged from 17 to 75 kg/m2, although all patients were obese
before surgery. Further demographic information is presented in
Table 1. As expected, both the BMI and the obesity-related
comorbidities were signiﬁcantly different between pre- and post-
operative patients.
In the 592 postoperative patients, the BMI before surgery was
47.7 (SD 8.7). In these patients, a median of 12 months (range 3
to 196) had elapsed between the initial operation and the survey.
There was a mixture of different bariatric procedures: gastric
bypass (48.2%), gastric banding (29.8%), one-anastomosis
gastric bypass (9.6%), sleeve gastrectomy (5.2%), biliopancre-
atic diversion (4.2%), and combined or other procedures (2.8%).
Health-related quality-of-life was signiﬁcantly lower in
patients before surgery than after surgery (Table 2). Both in
pre- and postoperative patients, utilities were signiﬁcantly lower
when measured by SF-6D compared to EQ-5D. Although utilities
using one of the two methods were closely correlated (Pearson’s
r = 0.682, Spearman’s r = 0.731), the SF-6D gave higher utility
scores than the EQ-5D. As shown in Figure 1, the difference
ranged between 0.13 and 0.16, without a detectable inﬂuence of
weight.
Table 1 Comparison of demographic characteristics between pre- and postoperative patients
Preoperative patients
(n = 302)
Postoperative patients
(n = 591)
Total sample
(n = 893)
Recruitment site
Frankfurt, Germany 113 287 400
Naples, Italy 65 84 149
Prague, Czechia 106 94 200
Barcelona, Spain 0 53 53
Málaga, Spain 18 73 91
Age (years) 40.4 (10.8) 41.5 (10.8) 41.2 (10.8)
Sex (n females) 224 (74.2%) 478 (80.9%) 702 (78.6%)
Body mass index (kg/m2) 46.0 (8.4) 34.9 (8.4) 38.9 (9.9)
Diabetes mellitus
Requiring oral drugs 40 (13.2%) 28 (4.7%) 68 (7,6%)
Requiring insulin 18 (6.0%) 10 (1.7%) 28 (3.1%)
Pulmonary disease
Requiring drug therapy 54 (17.9%) 26 (4.4%) 80 (9.0%)
Requiring CPAP treatment 17 (5.6%) 16 (2.7%) 33 (3.7%)
Metabolic disease
Laboratory parameters elevated 75 (24.8%) 38 (6.4%) 113 (12.7%)
Requiring regular drug therapy 44 (14.6%) 18 (3.0%) 62 (6.9%)
Cardiovascular disease
Abnormal ﬁndings or blood pressure 42 (14.0%) 48 (8.1%) 90 (10.1%)
Requiring regular drug therapy 101 (33.4%) 100 (16.9%) 201 (22.5%)
Knee arthritis
Pain or radiological evidence 71 (23.5%) 82 (13.9%) 153 (17.1%)
Requiring daily analgesics or surgery 35 (11.6%) 38 (6.4%) 73 (8.2%)
Values are shown as means (SD) or counts (percentages).All differences between pre- and postoperative patients (except age) are statistically signiﬁcant.
CPAP, continuous positive airway pressure.
Table 2 Comparison of health-related quality-of-life between pre- and postoperative patients
Preoperative patients Postoperative patients Total sample
SF-36 health domain scales
Physical functioning 51.5 (28.8) 75.3 (26.2) 67.3 (29.3)
Role-physical 50.8 (33.4) 73.4 (30.0) 65.8 (33.0)
Bodily pain 49.8 (31.3) 63.5 (32.1) 58.9 (32.5)
General health 52.4 (26.2) 68.1 (24.1) 62.8 (25.9)
Vitality 53.0 (15.7) 55.7 (16.5) 54.8 (16.3)
Social functioning 51.3 (24.2) 60.9 (28.5) 57.6 (27.5)
Role-emotional 45.5 (35.7) 60.5 (38.9) 55.5 (38.5)
Mental health 53.9 (32.8) 57.3 (32.9) 56.2 (32.9)
SF-6D utility score 0.624 (0.117) 0.733 (0.128) 0.699 (0.134)
MA-II single items (1 to 10 scale)
General mood (MA1) 6.1 (2.5) 7.7 (2.0) 7.1 (2.3)
Physical function (MA2) 4.9 (2.5) 7.1 (2.4) 6.4 (2.6)
Social relationships (MA3) 6.3 (2.9) 8.1 (2.1) 7.5 (2.5)
Ability to work (MA4) 6.3 (2.8) 7.8 (2.3) 7.3 (2.6)
Sexuality (MA5) 5.6 (3.2) 7.0 (2.7) 6.5 (3.0)
Eating behavior (MA6) 5.9 (2.3) 7.5 (2.1) 7.0 (2.3)
MA-II summary score 35.4 (12.1) 45.3 (9.8) 41.9 (11.6)
EQ-5D utility score 0.754 (0.217) 0.869 (0.144) 0.830 (0.180)
EQ-5D VAS utility 58.3 (23.7) 74.8 (19.3) 69.3 (22.3)
Values are shown as means (SD).
MA-II, Moorehead-Ardelt II questionnaire (6 to 60 scale).To convert to classical scale (-3 to 3) substract 6, divide by 9 and again substract 3.
EQ-5D, EuroQoL-5D; SF-6D, Short Form-6D;VAS, visual analog scale.
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Mapping the EQ-5D
The EQ-5D was well correlated to the MA-II scale (Pearson’s
r = 0.662, Spearman’s r = 0.677). The different regression
models are presented in Table 3. The inclusion of additional
covariates or nonlinear terms failed to improve the ﬁt of these
models. Speciﬁcally, the results of validation did not differ
between pre- and postoperative patients, patients with or
without comorbidity, or between different centers.
The R2 value was largest (0.441), when the model was based
on the six single items of the MA-II. Nevertheless, not all items
contributed signiﬁcantly to the ﬁt of the model. To use the same
variables as in the SF-6D-based model, the ﬁnal model (Table 4)
included only the items 1 to 5 of the MA-II:
Utility MA-II-based MA
MA
( ) = + ×( ) +
×( ) +
0 4293 0 0336 1
0 0071 2
0 00
. .
.
. 53 3
0 0107 4
0 0001 5
×( ) +
×( ) +
×( )
MA
MA
MA
.
.
This reduced item-based model gave an acceptable goodness-
of-ﬁt in the development sample (R2 = 0.446) but showed better
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Figure 1 Effect of increased body mass index on
utilities as estimated from EuroQoL-5D (squares,
upper line) and Short Form-6D (circles, lower line).
The number of patients per group was 59, 115, 171,
189, 147, 91, and 121, respectively.
Table 3 Model selection for prediction of EuroQoL-5D (EQ-5D)-based and Short Form-6D (SF-6D)-based utility values (based on development sample)
Speciﬁcation of model N patients R2 a SEa b SEb
EQ-5D = a + b1MA-II + error Scale-based 412 0.387 0.434 0.026 0.010* 0.001
EQ-5D = a + b1MA-II-1 Item-based 412 0.441 0.422 0.026 b1 = 0.033* 0.005
+ b2MA-II-2 b2 = 0.007 0.004
+ b3MA-II-3 b3 = 0.005 0.004
+ b4MA-II-4 b4 = 0.011* 0.004
+ b5MA-II-5 b5 < 0.001 0.003
+ b6MA-II-6 + error b6 = 0.003 0.004
EQ-5D = a + b1MA-II Covariate-adjusted 412 0.394 0.529 0.066 b1 = 0.009* 0.001
+ b2Age b2 = -0.001 0.001
+ b3Sex b3 = 0.031 0.017
+ b4BMI + error b4 = -0.001 0.001
SF-6D = a + b1MA-II + error Scale-based 367 0.547 0.321 0.019 0.009* <0.001
SF-6D = a + b1MA-II-1 Item-based 367 0.573 0.328 0.019 b1 = 0.023* 0.003
+ b2MA-II-2 b2 = 0.009* 0.003
+ b3MA-II-3 b3 = 0.007* 0.003
+ b4MA-II-4 b4 = 0.004 0.003
+ b5MA-II-5 b5 = 0.008* 0.002
+ b6MA-II-6 + error b6 = 0.001 0.003
SF-6D = a + b1MA-II Covariate-adjusted 367 0.556 0.426 0.046 b1 = 0.009* <0.001
+ b2Age b2 = -0.001 <0.001
+ b3Sex b3 = -0.023* 0.011
+ b4BMI + error b4 = 0.001 0.001
*Statistically signiﬁcant coefﬁcient.
MA-II, Moorehead-Ardelt II questionnaire.
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ﬁt in the validation sample (R2 = 0.550). Thus, the model
explains 55% of the EQ-5D variation. Mean and median values
for MAPE were 20% and 7% (interquartile range [IQR] 3% to
14%) in the development sample and 19% and 7% (IQR 3%
to 14%) in the validation sample.
Mapping the SF-6D
A good correlation between the SF-6D and the MA-II scale was
found (Pearson’s r = 0.734, Spearman’s r = 0.741). When com-
paring the scale-based and the item-based regression model,
goodness-of-ﬁt as measured by R2 was comparably high for
both models (0.573 vs. 0.547, Table 3). Again, there was no
effect of center or language on the results, and plotting the
regression residuals revealed no evidence of nonlinearity. In the
model, which used the six single items of the MA-II, the items
4 and 6 were uninformative for the prediction of utility. Nev-
ertheless, because item 4 was informative in the EQ-5D-based
model, the preferred model includes the ﬁrst ﬁve items of the
MA-II:
Utility MA-II-based MA
MA
( ) = + ×( ) +
×( ) +
0 3325 0 0232 1
0 0089 2
0 00
. .
.
. 68 3
0 0044 4
0 0086 5
×( ) +
×( ) +
×( )
MA
MA
MA
.
. .
Applying this model to the development and validation
sample, it explained 57.2% and 54.3% of the observed variation
in SF-6D utilities (Table 4). Mean and median values for MAPE
were 11% and 9% (IQR 4% to 14%) in the development sample
and 11% and 8% (IQR 4% to 14%) in the validation sample.
Comparison of Predictive Models
A statistical comparison of the errors between observed and
expected values (using MAPE data) conﬁrmed the superiority of
the EQ-5D-based mapping algorithm (P = 0.045 by Wilcoxon
test, n = 732).
Discussion
Bariatric surgery is an emerging ﬁeld in one of medicine’s most
dynamic eras. Because widespread acceptance of this treatment
option has come only recently, research on economic or HRQoL
issues in morbidly obese patients is still in its infancy. The results
of this study allow researchers to calculate preference-based
utility values from an HRQoL instrument that is commonly used
in bariatric surgery. By applying our algorithm to MA-II data
from randomized trials, the utilities of two different treatment
strategies could be assessed and compared.
The most critical aspect of a mapping algorithm is the
goodness-of-ﬁt it provides. In this study both algorithms
achieved values of R2 greater than 50% in the validation sample.
This is comparable to other recent studies carried out on patients
with obesity [23], prostate cancer [24], Crohn’s disease [25],
and growth hormone deﬁciency [26]. In these studies R2 values
ranged between 0.29 and 0.69. Similarly, the MAPE values of the
present study (7% to 9%) were in line with previous research on
abdominal diseases [25]. Therefore, the relationship between
MA-II and both SF-6D and EQ-5D appears to be strong enough
for predictive purposes.
We decided against using the EQ-5D VAS as a target variable
for modelling utility, because inconsistencies between VAS values
and EQ-5D-based utilities are known to be present in about
two-thirds of cases [27]. In the present study, VAS values were
clearly lower and more spread out than EQ-5D utilities.
Although the VAS allows for a direct valuation of health states,
our results probably suggest that VAS data tend to be less valid
and reliable, at least if respondents are assessing their own health
status rather than valuing hypothetical article cases.
We consider the heterogeneity of the present cohort as an
advantage of the study, because it increases the generalizability of
the results. If recruitment was restricted to only one type of
bariatric procedure, this would possibly prevent the usage of the
algorithm in other patient cohorts. For example, European sur-
geons traditionally have preferred gastric banding over gastric
bypass, although American surgeons do the opposite [28]. In this
regard, the cohort we studied is representative of the general
population of morbidly obese patients, including those who
received surgery.
Although previous research has used utility measures prima-
rily on overweight rather than obese patients [23,29,30], the BMI
for patients in this study ranged to extreme values. The fact that
BMI was uninformative for the regression model supports the
assertion that all estimated parameters are robust over the full
range from normal weight to morbid obesity. Furthermore, the
differences between the development and the validation sample
were relatively small. The majority of the estimated coefﬁcients
remained unchanged when additional parameters were added to
the model, which underpins the validity of the statistical model.
The sole reliance on a essentially linear regression model could
still be considered a shortcoming of the present study. In other
mapping studies, however, the use of additional methods (Jack-
knife and bootstrap analysis) yielded very similar results as com-
pared to multiple regression analysis.
Table 4 Model reﬁnement and cross-validation
Speciﬁcation of model Sample N patients R2 a SEa b SEb
EQ-5D = a + b1MA-II-1 Development 414 0.446 0.429 0.024 b1 = 0.034* 0.005
+ b2MA-II-2 b2 = 0.007* 0.003
+ b3MA-II-3 b3 = 0.005 0.004
+ b4MA-II-4 b4 = 0.011* 0.004
+ b5MA-II-5 + error b5 = 0.000 0.003
Validation 410 0.551
SF-6D = a + b1MA-II-1 Development 368 0.572 0.333 0.018 b1 = 0.023* 0.003
+ b2MA-II-2 b2 = 0.009* 0.002
+ b3MA-II-3 b3 = 0.007* 0.003
+ b4MA-II-4 b4 = 0.004 0.003
+ b5MA-II-5 + error b5 = 0.009* 0.002
Validation 372 0.543
*Statistically signiﬁcant coefﬁcient.
EQ-5D, EuroQoL-5D; MA-II, Moorehead-Ardelt II questionnaire; SF-6D, Short Form-6D.
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Although the MA-II is well accepted by the surgical commu-
nity, this study also detected some inherent problems of this
questionnaire. In the prediction of utility values not all of the
items were found to be signiﬁcantly associated with EQ-5D and
SF-6D-based score values. Not unexpectedly, the more generic
items of the MA-II were highly correlated to generic HRQoL and
utility values. On the other hand, the most disease-speciﬁc sixth
item of the MA-II had to be removed from the estimation algo-
rithm. This can be possibly explained by the fact that many
patients see their change in eating habits not as an improvement
but as a restriction in HRQoL, because they were (to some
extent) enjoying their supranormal preoperative food intake.
Another possible explanation is that a healthy attitude to food
truly is an aspect of HRQoL, but both EQ-5D and SF-6D fail to
record it. Further validation studies on the MA-II need to be
performed to examine how well this item is able to discriminate
between patients with high and low HRQoL. It also is necessary
to assess the predictive properties of other measures that can be
used in obese patients.
It is known that themethod of data collection has an impact on
the responses. Usually, HRQoL data tend to be more favorable
when data are collected by personal interviews. On the other
hand, patients wishing bariatric surgery might tend to aggravate
their symptoms in psychometric tests to avoid being denied
surgery. In this study, patients completed the questionnaires them-
selves in the outpatient clinic. Patients were explicitly informed
that their responses would not affect their health care in any
manner. This reduces the potential for biased responses. Even if
the way of data collection caused some bias, the bias would affect
all questionnaires in more or less the same way and therefore it
would not affect the correlation between the questionnaires.
The question which of the two utility instruments should be
used in the estimations is not easy to answer, although median
estimation error was slightly smaller for the EQ-5D-based than
for the SF-6D-based regression models. From previous compari-
son studies it is known that the SF-6D can better describe nearly
normal health states [31,32], such as in patients with mild
residual overweight and no further health problems. Our results
are supportive of mild ceiling effects of the EQ-5D (Fig. 1).
Because the EQ-5D was also better accepted by patients, we
would recommend applying the EQ-5D-based mapping algo-
rithm. Alternatively, the use of an MA-II scale-based algorithm
also would provide reliable estimates of utility values.
Principally, it appears preferable to use a preference-based
measure such as the EQ-5D or the SF-6D rather than a disease-
speciﬁc instrument. Ideally, the present study would also have
included further direct utility measures such as standard gamble
or time trade-off [27]. Nevertheless, the sensitivity of generic
instruments may be lower [17,33]. Second, a recent review of
derivation studies found that disease-speciﬁc instruments allow
calculation of utilities with similar precision as generic instru-
ments [34]. Third, the application of nondisease-speciﬁc instru-
ments is not possible in many clinical settings. In these situations,
it is valid to estimate utilities directly from MA-II items, since this
study has detected only a small risk of error for this algorithm.
The EQ-5D-based algorithm seems to be preferable, mainly
because of the generally better psychometric characteristics of
this measure in patients with mild or moderate disease, but this
needs to be conﬁrmed in future studies. According to the distri-
bution of the sample, we believe that the utility model is suitable
for all patients with a BMI greater than 30 and those who have
undergone bariatric surgery.
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